Spotlight on Hematology

Credits: 1.00 CME
Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma
Joseph Mikhael, MD, MEd, FRCPC, FACP
Penn State College of Medicine

Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma

Start

Provided By

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: August 8, 2017
Expires: August 8, 2018
1 hour to complete

Target Audience

Community medical oncologists, radiation oncologists, hematologists, hematologist/oncologists, internists, oncology nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians involved in the management of patients with MM.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss new treatment options stemming from recent FDA approvals in the relapsed/refractory setting.
  2. Review recently published clinical trial data on the efficacy and safety of emerging treatments for relapsed/refractory patients.
  3. Describe recent changes to clinical practice guidelines affecting care for patients with relapsed/refractory disease.
  4. Summarize best practices with respect to communication and coordination among members of the multidisciplinary myeloma care team.

Activity Description

This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma.

Statement of Educational Need

The treatment landscape for multiple myeloma (MM) is rapidly evolving. FDA approval of 10 new agents in the past 12 years has changed the natural history of this plasma cell malignancy. Survival among relapsed/refractory patients has doubled, while survival among newly diagnosed patients has improved by 50%. Some authorities now claim that young, fit patients with favorable risk factors can be cured with aggressive treatment; however, the management of patients who relapse remains a challenge.

Agenda

  • Introduction
  • Case study 1
  • Recent FDA approvals and new options in relapsed/refractory setting
  • Updates to clinical practice guidelines
    • US guidelines
    • International guidelines
    • Teaching point: Most important updates related to treating relapsed/refractory patients
  • Clinical trials in MM
    • Novel targets and pathways
    • Novel agents
    • Novel combinations and treatment strategies
    • Teaching point: Clinical trials most relevant to treating relapsed/refractory patients
  • Case study 2
  • Team-based approaches to care
    • Importance of team-based care in improving patient outcomes
    • Supportive roles of various multidisciplinary team members
    • Best practices in communication and care coordination
    • Nursing and pharmacy implications of treating with monoclonal antibodies
    • Toxicity management
    • Insurance approval
  • Conclusion

Presenter

Joseph R. Mikhael MD, MEd, FRCPC, FACP
Professor of Medicine
Mayo College of Medicine
Associate Dean
Mayo School of Graduate Medical Education
Deputy Director – Education Mayo Clinic Cancer Center
Phoenix, AZ


Additional Content Development Faculty

Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders
Director, Clinical Research in Hematologic Malignancies
Clinical Professor of Medicine, UNC-Chapel Hill School of Medicine
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute/Carolinas HealthCare System
Charlotte, NC

Ajai Chari, MD, PhD
Associate Professor of Medicine
Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure of Conflict of Interest

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Dr. Mikhael has disclosed the following:
Research Grant: AbbVie, Celgene, Sanofi

Dr. Usmani has disclosed the following:
Speakers Bureau: Amgen, Celgene, Takeda
Consultant/Advisor: Amgen, Celgene, Janssen, SkylineDX
Research Grant: Amgen, Celgene, Janssen, Takeda, Sanofi, Array BioPharma

Dr. Chari has disclosed the following:
Consultant/Advisor: Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Millennium, Amgen
Research Grant: Array BioPharma, Celgene, Janssen, Novartis, Millennium, Onyx, Pharmacyclics

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in or receiving credit for this educational activity. Credit is awarded to participants who score 80% or better on the post-test.

Statement of Commercial Support

Supported by independent educational grants from Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Disclaimer Statement / Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; or Takeda Oncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Contact Information for Questions about the Activity

For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6194-18-T.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Hematology Presentations

0.25 CME / CNE / CPE
Rush University Medical Center
Updates from the National Multiple Myeloma Rounds Series: Focus on Amyloidosis

Updates from the National Multiple Myeloma Rounds Series: Focus on Amyloidosis

Start

Faculty

Agne Paner, MD (CME Course Director)
Assistant Professor of Medicine at Rush University Medical Center,
Division of Hematology/Oncology and Stem Cell Transplant
Director, Coleman Foundation Comprehensive Multiple Myeloma Clinic
Rush University Medical Center
Chicago, IL

Agne Paner, MD has disclosed having the following financial arrangements or affiliations with the commercial interests listed below whose products or services may be mentioned in this activity.
Advisory Board: Takeda Oncology
Member, Speakers’ Bureau: Celgene, Onyx/Amgen
Consultant: Takeda Oncology


Kimberly Lynch
Planner/Manager
PleXus Communications
Kim Lynch has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Michaela Ryan, PhD
PleXus Communications
Michaela Ryan, PhD has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Accredited By

Rush University Medical Center

Co-provided By

Activity Details

Free CME/CNE/CPE
0.25 AMA PRA Category 1 Credit
0.25 Contact Hour(s)
Released: December 21, 2017
Expires: December 20, 2018
20 minutes to complete

Goals (Purpose) of Program

To provide learners with a greater ability to formulate optimal evidence based strategies for the individualized treatment of their patients with multiple myeloma.

Learning Objectives

At the completion of this module, participants should be able to:

  • Apply current diagnostic approaches to accurately identify the type of amyloidosis, measure the extent of organ involvement, and determine the patient’s prognosis
  • Prescribe the optimal treatment plan for patients with amyloidosis
  • Identify patients with amyloidosis who would benefit from autologous stem cell transplant

Target Audience

This activity is designed to meet the needs of healthcare professionals involved in the treatment of patients with multiple myeloma.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours.

Rush University Medical Center designates this knowledge-based CPE activity 0622-0000-17-056-H01-P for 0.25 contact hours for pharmacists.

This activity is being presented without bias and with commercial support.

Requirements for Successful Completion

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 2 out of 3 or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Amgen, Celgene Corporation, Incyte Corporation, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CNE / CPE
Rush University Medical Center
Updates from the National Multiple Myeloma Rounds Series: Focus on Relapsed Multiple Myeloma

Updates from the National Multiple Myeloma Rounds Series: Focus on Relapsed Multiple Myeloma

Start

Faculty

Agne Paner, MD (CME Course Director)
Assistant Professor of Medicine at Rush University Medical Center,
Division of Hematology/Oncology and Stem Cell Transplant
Director, Coleman Foundation Comprehensive Multiple Myeloma Clinic
Rush University Medical Center
Chicago, IL

Agne Paner, MD has disclosed having the following financial arrangements or affiliations with the commercial interests listed below whose products or services may be mentioned in this activity.
Advisory Board: Takeda Oncology
Member, Speakers’ Bureau: Celgene, Onyx/Amgen
Consultant: Takeda Oncology


Kimberly Lynch
Planner/Manager
PleXus Communications
Kim Lynch has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Michaela Ryan, PhD
PleXus Communications
Michaela Ryan, PhD has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Accredited By

Rush University Medical Center

Co-provided By

Activity Details

Free CME/CNE/CPE
0.25 AMA PRA Category 1 Credit
0.25 Contact Hour(s)
Released: December 21, 2017
Expires: December 20, 2018
20 minutes to complete

Goals (Purpose) of Program

To provide learners with a greater ability to formulate optimal evidence based strategies for the individualized treatment of their patients with multiple myeloma.

Learning Objectives

At the completion of this module, participants should be able to:

  • Choose among treatment options available for patients with early relapsed multiple myeloma
  • Identify which patients could benefit from salvage transplant in relapsed multiple myeloma
  • Optimize treatment plan for patient with relapsed refractory multiple myeloma
  • Manage disease and treatment complications in patients with relapsed multiple myeloma

Target Audience

This activity is designed to meet the needs of healthcare professionals involved in the treatment of patients with multiple myeloma.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours.

Rush University Medical Center designates this knowledge-based CPE activity 0622-0000-17-058-H01-P for 0.25 contact hours for pharmacists.

This activity is being presented without bias and with commercial support.

Requirements for Successful Completion

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 2 out of 3 or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Amgen, Celgene Corporation, Incyte Corporation, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
Penn State College of Medicine
Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma

Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma

Start

Provided By

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: August 8, 2017
Expires: August 8, 2018
1 hour to complete

Target Audience

Community medical oncologists, radiation oncologists, hematologists, hematologist/oncologists, internists, oncology nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians involved in the management of patients with MM.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss new treatment options stemming from recent FDA approvals in the relapsed/refractory setting.
  2. Review recently published clinical trial data on the efficacy and safety of emerging treatments for relapsed/refractory patients.
  3. Describe recent changes to clinical practice guidelines affecting care for patients with relapsed/refractory disease.
  4. Summarize best practices with respect to communication and coordination among members of the multidisciplinary myeloma care team.

Activity Description

This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma.

Statement of Educational Need

The treatment landscape for multiple myeloma (MM) is rapidly evolving. FDA approval of 10 new agents in the past 12 years has changed the natural history of this plasma cell malignancy. Survival among relapsed/refractory patients has doubled, while survival among newly diagnosed patients has improved by 50%. Some authorities now claim that young, fit patients with favorable risk factors can be cured with aggressive treatment; however, the management of patients who relapse remains a challenge.

Agenda

  • Introduction
  • Case study 1
  • Recent FDA approvals and new options in relapsed/refractory setting
  • Updates to clinical practice guidelines
    • US guidelines
    • International guidelines
    • Teaching point: Most important updates related to treating relapsed/refractory patients
  • Clinical trials in MM
    • Novel targets and pathways
    • Novel agents
    • Novel combinations and treatment strategies
    • Teaching point: Clinical trials most relevant to treating relapsed/refractory patients
  • Case study 2
  • Team-based approaches to care
    • Importance of team-based care in improving patient outcomes
    • Supportive roles of various multidisciplinary team members
    • Best practices in communication and care coordination
    • Nursing and pharmacy implications of treating with monoclonal antibodies
    • Toxicity management
    • Insurance approval
  • Conclusion

Presenter

Joseph R. Mikhael MD, MEd, FRCPC, FACP
Professor of Medicine
Mayo College of Medicine
Associate Dean
Mayo School of Graduate Medical Education
Deputy Director – Education Mayo Clinic Cancer Center
Phoenix, AZ


Additional Content Development Faculty

Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders
Director, Clinical Research in Hematologic Malignancies
Clinical Professor of Medicine, UNC-Chapel Hill School of Medicine
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute/Carolinas HealthCare System
Charlotte, NC

Ajai Chari, MD, PhD
Associate Professor of Medicine
Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure of Conflict of Interest

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Dr. Mikhael has disclosed the following:
Research Grant: AbbVie, Celgene, Sanofi

Dr. Usmani has disclosed the following:
Speakers Bureau: Amgen, Celgene, Takeda
Consultant/Advisor: Amgen, Celgene, Janssen, SkylineDX
Research Grant: Amgen, Celgene, Janssen, Takeda, Sanofi, Array BioPharma

Dr. Chari has disclosed the following:
Consultant/Advisor: Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Millennium, Amgen
Research Grant: Array BioPharma, Celgene, Janssen, Novartis, Millennium, Onyx, Pharmacyclics

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in or receiving credit for this educational activity. Credit is awarded to participants who score 80% or better on the post-test.

Statement of Commercial Support

Supported by independent educational grants from Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Disclaimer Statement / Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; or Takeda Oncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Contact Information for Questions about the Activity

For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6194-18-T.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.